Search results
Janssen adopts J&J name as part of global rebranding effort
Pharmaceutical Technology via Yahoo Finance· 1 month agoAn iconic name in the pharma industry has vanished in the UK as Janssen – Johnson & Johnson’s (J&J)...
Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients
Benzinga via Yahoo Finance· 2 years agoJanssen Biotech Inc, a Johnson & Johnson (NYSE: JNJ) unit, received European conditional approval...
Alkermes (ALKS) Gets Final Award in Janssen Arbitration, Ups View
Zacks via Yahoo Finance· 1 year agoAlkermes ALKS received a final award in its arbitration proceedings with Janssen Pharmaceuticals, a...
FATE To End Janssen Deal and Prioritize Pipeline Development
Zacks via Yahoo Finance· 1 year agoFate Therapeutics, Inc. FATE announced that it has declined a proposal from Janssen Biotech, Inc., a...
Johnson & Johnson's Drug Acquired Via Momenta Deal Shows Encouraging Data In Fetal Disorder
Benzinga via Yahoo Finance· 1 year agoJanssen, a unit of Johnson & Johnson (NYSE: JNJ), announced topline results from the...
Johnson & Johnson's HIV Vaccine Regimen Does Not Prevent Infection, Phase 3 Study Shows
Benzinga via Yahoo Finance· 1 year agoThe Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) announced the results of an...
Janssen-Cilag seeks expanded EMA approval for TREMFYA
Pharmaceutical Technology via Yahoo Finance· 1 month agoJohnson & Johnson company Janssen-Cilag International has filed applications with the European...
Biotech Stock Roundup: PTGX Gains on Study Data, BMRN Faces Setback & More
Zacks via Yahoo Finance· 1 year agoThe biotech sector was in focus with key pipeline and regulatory updates. Among these, BMRN was down...
Big Pharma's Johnson & Johnson under investigation in South Africa over 'excessive' drug prices
AP Finance via Yahoo Finance· 9 months agoU.S.-based pharmaceuticals company Johnson & Johnson is being investigated in South Africa for...
FATE's Q4 Loss Narrower Than Expected, Pipeline in Focus
Zacks via Yahoo Finance· 1 year agoFate Therapeutics FATE reported a loss of 58 cents per share in the fourth quarter of 2022, narrower...